Diligence memo · auto-generated · as of July 3, 2026
GPI Finco (Canada) Inc.
GPI Finco (Canada) Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
GPI Finco (Canada) Inc. operates in Pharmaceuticals, based in LANSING.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
GPI Finco (Canada) Inc. has raised $23M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $23M on 2019-03-04.
Most recent recorded round closed around 2019-03-04.
Valuation (modeled)modeled
Provath models GPI Finco (Canada) Inc. at approximately $778M (range $48M–$3.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.57× the median modeled value of Series B Pharmaceuticals companies in 2019–2021 (61 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 7.3 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 68% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 86% of those peers.
Closest niche peers: Evolus, Inc., HOOKIPA Pharma Inc., ESSA Pharma Inc., Pieris Pharmaceuticals, Inc., Amylyx Pharmaceuticals, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.